Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.790
-0.070 (-2.45%)
At close: Jun 22, 2026, 4:00 PM EDT
2.800
+0.010 (0.36%)
After-hours: Jun 22, 2026, 7:07 PM EDT
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
108
Market Cap
199.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 151.12M |
| Arcturus Therapeutics Holdings | 54.71M |
| Q32 Bio | 53.74M |
| Keros Therapeutics | 33.18M |
| Alector | 18.42M |
| ProQR Therapeutics | 15.73M |
| Camp4 Therapeutics | 3.93M |
| Humacyte | 2.02M |
NKTX News
- 12 days ago - Nkarta Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Nkarta price target lowered to $9 from $25 at Evercore ISI - TheFly
- 5 weeks ago - Nkarta reports Q1 EPS (37c), consensus (37c) - TheFly
- 5 weeks ago - Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Nkarta Earnings release: Q1 2026 - Filings
- 5 weeks ago - Nkarta Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Nkarta Slides: Corporate presentation - Filings
- 2 months ago - Nkarta Proxy statement: Proxy filing - Filings